Progress in systemic therapy of advanced hepatocellular carcinoma.

World J Gastroenterol

Xin-Lei Gong, Shu-Kui Qin, Chinese People's Liberation Army Cancer Center, Bayi Hospital, Nanjing 210002, Jiangsu Province, China.

Published: August 2016

Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of common malignancies worldwide, and prevalent among the Chinese population. A diagnosis of early stage HCC has proven to be very difficult because of its insidious feature in onset and development. At the time of diagnosis, most HCC cases are locally advanced and/or distant metastatic, which results in difficulty to be treated and poor prognosis. For advanced HCC, systemic therapy is frequently adopted as an important palliative method. In recent years, clinical studies and observations have often reported about systemic anti-cancer therapy of advanced HCC, including molecular target therapy, systemic chemotherapy and immunotherapy. In this article, we review these treatment modalities to provide a reference for clinicians.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970483PMC
http://dx.doi.org/10.3748/wjg.v22.i29.6582DOI Listing

Publication Analysis

Top Keywords

systemic therapy
8
therapy advanced
8
hepatocellular carcinoma
8
advanced hcc
8
hcc
5
progress systemic
4
therapy
4
advanced
4
advanced hepatocellular
4
carcinoma primary
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!